Immuno-Oncology Therapy is a Targeted Answer to Cancer

Cancer is the second highest cause of death worldwide and is associated with approximately 10 million deaths per year.¹ To alleviate cancer outcomes, various types of therapeutic agents continue to be developed. Although traditional treatments like chemotherapy and radiation have been the prevalent option for cancer treatment, the development of immuno-oncology therapies can provide high specificity and longer-lasting remissions.²

Immuno-oncology therapies harness the power of the host’s immune system to prevent, control, and eliminate cancer. The role of the immune system is to eliminate potential threats to our health. The system works well, but cancer cells sometimes slip past this mechanism. Immuno-oncology is an emerging field that enables the host’s immune system to better recognize and target cancer cells.

Once you see the full value of metabolomics, the only remaining question is who does it best? While many laboratories have metabolite profiling or analytical chemistry capabilities, comprehensive metabolomics technologies are extremely rare. Accurate, unbiased metabolite identification across the entire metabolome introduces signal-to-noise challenges that very few labs are equipped to handle. Also, translating massive quantities of data into actionable information is slow, if not impossible, for most because proper interpretation takes two things that are in short supply: experience and a comprehensive database.